Aravive Biologics appoints Dr Stephen Eck as CEO alongside Dr Ray Tabibiazar as Chairman of the Board of Directors

– USA, TX –  Aravive Biologics today announced the appointment of Stephen Eck, M.D., Ph.D. as President and Chief Executive Officer. Dr. Eck was formerly Vice President of Oncology Medical Sciences at Astellas Pharma Global Development, Inc. Ray Tabibiazar, M.D., founding President and CEO of Aravive, remains as Chairman of the company’s Board of Directors.

“Stephen has an impressive track-record of oncology drug and biomarker development at prominent pharmaceutical companies, as well as a close relationship to Houston’s M.D. Anderson Cancer Center as a member of the Advisory Board for their oncology Moonshot Program,” said Dr. Tabibiazar. “We welcome his expertise and leadership to the Aravive team as we prepare to advance our lead drug candidate, Aravive-S6, into human clinical testing in 2018.”

“I am very excited to be joining Aravive at this point in the company’s development,” said Dr. Eck. “Aravive-S6 is a novel and promising agent that has shown in preclinical trials the potential to improve the treatment of cancer in combination with a wide range of other approaches, including chemotherapeutic drugs, radiation, PARP inhibitors and checkpoint inhibitors. I look forward to helping Aravive realize the full potential that I believe Gas6/AXL inhibition can bring to the treatment of cancer.”

Prior to joining Astellas Pharma, Stephen Eck served as Vice President, Translational Medicine & Pharmacogenomics at Eli Lilly and Company, where his group developed the biomarkers and companion diagnostics needed for study-specific decision making and for tailoring biotherapeutics to unique patient populations. Prior to joining Lilly, he served in a variety of oncology and neuroscience drug development leadership roles at Pfizer, Inc. Dr. Eck is a board-certified hematologist, who holds a Ph.D. in chemistry from Harvard University and received his M.D. degree from the University of Mississippi School of Medicine. He serves on the Board of Directors of Luminex Corporation, a Texas-based life sciences company, is a Fellow of the American Association for the Advancement of Science, and is Chairman of the Board of Directors of the Personalized Medicine Coalition.

About Aravive Biologics, Inc.

Aravive Biologics is a privately held, late pre-clinical stage biopharmaceutical company developing novel, highly selective cancer therapies that treat serious malignancies while sparing normal healthy cells. The company’s lead program is focused on the GAS6/AXL pathway, where activation appears to play a critical role in multiple types of cancer malignancies by promoting tumor metastasis and cell survival. Aravive Biologics has generated strong preclinical data for its lead drug candidate, Aravive-S6, in both acute myeloid leukemia (AML) and solid tumors including ovarian, pancreatic, and breast cancers. The company is based in Houston, Texas, and receives support from the Cancer Prevention & Research Institute of Texas (CPRIT).

For more information: http://www.aravive.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>